← Human Trials & Peer-Reviewed Studies
The severity of chronic heart failure due to coronary artery disease predicts the endocrine effects of short-term growth hormone administration.
Plain-language guide to PMID 10770193 (2000): randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 3 patients.
Key Facts
- PMID
- 10770193
- Journal
- The Journal of clinical endocrinology and metabolism
- Year
- 2000
- Study type
- Randomized Controlled Trial
- Authors
- Osterziel KJ et al. (4 authors)
- DOI
- 10.1210/jcem.85.4.6575
What This Study Did, in Plain Language
What Was Tested
Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.
Treatment with human recombinant GH has yielded conflicting results in patients with heart failure.
As GH sensitivity may be important for treatment effects, the present study evaluated GH secretion and sensitivity in noncachectic patients with ischemic heart failure.
Who Took Part
The study group was 3 patients.
The age groups tagged for this paper are middle-aged adults, men only.
How the Study Was Run
The design is described as randomized.
Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Cardiac function was assessed by echocardiography.
What Was Measured
As GH sensitivity may be important for treatment effects, the present study evaluated GH secretion and sensitivity in noncachectic patients with ischemic heart failure.
Serum insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and 24-h urinary GH excretion as a measure of pituitary GH secretion were determined at baseline and on days 5 and 9.
PubMed files the paper under topics including Cardiac Output, Low, Coronary Disease, Echocardiography, Human Growth Hormone, Insulin-Like Growth Factor Binding Protein 3, Insulin-Like Growth Factor I and Myocardial Infarction.
What This Means in Plain Language
The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 3 patients.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 2000 (The Journal of clinical endocrinology and metabolism), a journal based in United States.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.